Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

NCT02557620 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of daily versus weekly injections of semaglutide in people with diabetes and healthy volunteers.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 113 people

Who can join Ages 18–55 · all sexes Healthy volunteers accepted.

Timeline Started 2015-09 · est. completion 2016-04

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02557620 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to compare the steady-state exposure of semaglutide administered subcutaneously once daily to semaglutide administered subcutaneously once weekly in healthy subjects.

Treatments tested

semaglutide Drug

Administered subcutaneously (s.c., under the skin)once daily or once weekly.
placebo Drug

Administered subcutaneously (s.c., under the skin)once daily or once weekly.

Main thing measured	Area under the semaglutide concentration-time curves
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Healthy
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02557620 ↗